This study tests a new drug called INBRX-109 for people with advanced solid tumors, including sarcomas, which are types of cancer. It is a phase 1 trial, meaning it is the first time this drug is being tested in humans. The study will look at how safe the drug is and how it affects the body.

Eligibility: Participants should be between 12 and 84 years old, depending on the specific type of tumor. They must have tumors that cannot be treated with standard therapies. They must also have good organ function and good overall health.

Exclusion: People who have used similar drugs, had certain treatments recently, or have other health issues, like severe liver disease, are not allowed. Pregnant or nursing women cannot join.

• The study is divided into three parts and is not randomized, meaning participants will all get the study drug.
• Participants will need to stop certain medications and treatments before joining.
• There will be regular health checks and monitoring throughout the study.

This trial provides a new treatment opportunity for those with few other options, but it's important to consider the risks and requirements before joining.